Corner Office Conversation with Dilip Shanghvi, Chairman of Sun Pharma and Glenn Saldanha, Managing Director at Glenmark Pharma
In a candid, unscripted exchange, India’s pharma titans peeled back the mythology of overnight success to reveal a harder truth: conviction compounded over decades. What began as two products and a bet on neglected therapy areas evolved into a multibillion-dollar enterprise riding India’s epidemiological shift. Innovation, they argued, is a long game—scarred by failed trials, investor backlash, and capital droughts—yet redeemed by landmark deals and scientific persistence. In this episode, host Vikas Dandekar talks to Dilip Shanghvi, Chairman of Sun Pharma and Glenn…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.